Aligned Genetics, Inc. (KOSDAQ:238120)
South Korea · Delayed Price · Currency is KRW 4,855.00
-155.00 (-3.09%)
At close: Feb 27, 2026
Aligned Genetics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 17,351 | 15,778 | 15,215 | 13,753 | 11,762 | 7,957 |
Other Revenue | - | - | -0 | -0 | - | - |
| 17,351 | 15,778 | 15,215 | 13,753 | 11,762 | 7,957 | |
Revenue Growth (YoY) | 15.68% | 3.70% | 10.63% | 16.92% | 47.82% | 2.10% |
Cost of Revenue | 5,382 | 4,629 | 4,556 | 4,998 | 4,424 | 3,425 |
Gross Profit | 11,969 | 11,148 | 10,659 | 8,755 | 7,338 | 4,532 |
Selling, General & Admin | 6,146 | 5,619 | 5,125 | 4,287 | 3,791 | 3,446 |
Research & Development | 2,465 | 2,292 | 1,684 | 1,079 | 943.58 | 816.17 |
Amortization of Goodwill & Intangibles | 20.17 | 15.7 | 19.3 | 21.33 | 35.46 | 45.76 |
Other Operating Expenses | 103.5 | 96.87 | 84.21 | 77.31 | 59.34 | 35.92 |
Operating Expenses | 9,071 | 8,369 | 7,322 | 5,906 | 5,159 | 4,785 |
Operating Income | 2,898 | 2,780 | 3,337 | 2,849 | 2,179 | -253.48 |
Interest Expense | -65.64 | -169.15 | -214.88 | -165.96 | -28.88 | -82.83 |
Interest & Investment Income | 227.41 | 405.32 | 161.61 | 168.16 | 27.71 | 163.3 |
Earnings From Equity Investments | 29.26 | - | - | - | - | -79.28 |
Currency Exchange Gain (Loss) | 991.53 | 1,530 | 302.06 | 17.89 | 353.05 | -255.15 |
Other Non Operating Income (Expenses) | 55.65 | 33.59 | 8.09 | 83.88 | -238.9 | 31.32 |
EBT Excluding Unusual Items | 4,136 | 4,579 | 3,594 | 2,953 | 2,292 | -476.12 |
Gain (Loss) on Sale of Investments | -331.42 | -36.7 | -147.75 | -510.71 | 1,507 | 944.36 |
Gain (Loss) on Sale of Assets | -0 | - | -22.04 | - | 13.94 | - |
Pretax Income | 3,805 | 4,542 | 3,424 | 2,442 | 3,813 | 468.23 |
Income Tax Expense | 61.93 | 414.26 | 188.16 | 109.5 | -1,729 | - |
Net Income | 3,743 | 4,128 | 3,236 | 2,333 | 5,542 | 468.23 |
Net Income to Common | 3,743 | 4,128 | 3,236 | 2,333 | 5,542 | 468.23 |
Net Income Growth | 51.02% | 27.57% | 38.72% | -57.90% | 1083.53% | 301.10% |
Shares Outstanding (Basic) | 14 | 14 | 14 | 14 | 14 | 10 |
Shares Outstanding (Diluted) | 14 | 14 | 14 | 14 | 14 | 10 |
Shares Change (YoY) | -1.33% | - | - | - | 38.26% | -27.67% |
EPS (Basic) | 263.72 | 287.09 | 225.05 | 162.23 | 385.40 | 45.02 |
EPS (Diluted) | 263.63 | 287.00 | 225.00 | 162.00 | 385.40 | 45.00 |
EPS Growth | 53.00% | 27.56% | 38.89% | -57.97% | 756.45% | 462.50% |
Free Cash Flow | 132.61 | 2,808 | 1,970 | 220.98 | -3,171 | -60.76 |
Free Cash Flow Per Share | 9.34 | 195.26 | 137.01 | 15.37 | -220.57 | -5.84 |
Gross Margin | 68.98% | 70.66% | 70.06% | 63.66% | 62.38% | 56.95% |
Operating Margin | 16.70% | 17.62% | 21.93% | 20.72% | 18.52% | -3.19% |
Profit Margin | 21.57% | 26.16% | 21.27% | 16.96% | 47.12% | 5.88% |
Free Cash Flow Margin | 0.76% | 17.79% | 12.95% | 1.61% | -26.96% | -0.76% |
EBITDA | 3,457 | 3,355 | 3,968 | 3,499 | 2,718 | 422.59 |
EBITDA Margin | 19.92% | 21.27% | 26.08% | 25.45% | 23.10% | 5.31% |
D&A For EBITDA | 558.59 | 575.74 | 631.38 | 650.38 | 538.59 | 676.07 |
EBIT | 2,898 | 2,780 | 3,337 | 2,849 | 2,179 | -253.48 |
EBIT Margin | 16.70% | 17.62% | 21.93% | 20.72% | 18.52% | -3.19% |
Effective Tax Rate | 1.63% | 9.12% | 5.50% | 4.48% | - | - |
Advertising Expenses | - | 359.22 | 261.67 | 243.86 | 96.94 | 229.45 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.